Latest News

BRAFTOVI and MEKTOVI drug combination receives positive CHMP opinion for treating metastatic melanoma

Pierre Fabre today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of BRAFTOVI® and MEKTOVI® in combination for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation.

Source link

Related posts

Combination of antibiotics prevents cancer cells from motoring


How empowered patients are taking a more active role in their healthcare


Pumped Breast Milk Falls Short of Direct Nursing


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy